ERalpha-targeted pegylation near-infrared fluorescent probe as well as preparation method and application of ERalpha-targeted pegylation near-infrared fluorescent probe

The use of ERα-targeted polyethylene glycol-based near-infrared fluorescent diagnostic probes has solved the problem of insufficient specificity of fluorescent probes in breast cancer imaging in existing technologies. It achieves highly efficient targeting, real-time monitoring, and high-contrast tumor imaging, significantly inhibits the growth of breast cancer cells, and improves the precision and efficacy of breast cancer treatment.

CN118903481APending Publication Date: 2024-11-08WUCHANG UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411220080.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing fluorescent probes suffer from insufficient specificity and non-specific background signals in breast cancer imaging, leading to reduced imaging specificity and accuracy. Furthermore, traditional treatment methods have toxic side effects on normal tissues.

Method used

An ERα-targeted polyethylene glycol-modified near-infrared fluorescent diagnostic probe was designed. By integrating the polyethylene glycolation strategy with the tumor microenvironment response mechanism, 7-oxabicyclo[2.2.1]hepten sulfonamide was linked to the PEG-modified fluorophore dicyanomethylene-4H-pyran to achieve precise targeted drug delivery and tumor microenvironment response, thereby enhancing the retention ability of the fluorophore in the tumor.

Benefits of technology

It achieves highly efficient targeted binding to ERα, provides high-contrast and durable tumor imaging, monitors ERα protein degradation in real time, significantly inhibits the growth of MCF-7 breast cancer cells, and improves the precision and efficacy of breast cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903481A_ABST
    Figure CN118903481A_ABST
Patent Text Reader

Abstract

The invention discloses an ERalpha-targeted pegylation near-infrared fluorescent probe as well as a preparation method and application thereof. According to the probe, a pegylation strategy and a tumor microenvironment response mechanism are integrated, and 7-oxabicyclo [2.2. 1] heptylene sulfonamide with an efficient ERalpha protein degradation function is connected with fluorophore dicyanomethylene-4H-pyran modified by polyethylene glycol through ester bonds. The probe provided by the invention realizes accurate targeted drug delivery, and enhances the retention capacity of fluorophores in tumors by virtue of a tumor microenvironment response mechanism, thereby providing high contrast and lasting in-vivo tumor imaging effect. The probe can effectively inhibit growth of MCF-7 breast cancer cells, real-time monitoring of ERalpha protein degradation is achieved, and breakthrough is brought to accuracy and curative effect of breast cancer treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine and tumor diagnosis and treatment technology, and specifically to an ERα-targeted PEGylated near-infrared fluorescent probe and its preparation method and application. The probe is used for targeted degradation and efficient imaging of ERα protein, aiming to provide an innovative, efficient and widely applicable method for the treatment of breast cancer. The present invention integrates cross-disciplinary innovations such as fluorescent molecule design, biomedical imaging, and chemical synthesis, and provides a new strategy for real-time visualization of tumor diagnosis and treatment processes. Background Art

[0002] Breast cancer is one of the most common malignant tumors worldwide, and its morbidity and mortality rates are increasing year by year. Estrogen receptor α (ERα) plays a key role in the occurrence and development of breast cancer, and ERα-positive breast cancer patients account for more than 70% of all breast cancer cases. Therefore, targeted therapy against ERα has become an important strategy for the treatment of breast cancer. Traditional breast cancer treatments, such as chemotherapy and radiotherapy, usually have toxic side effects on normal tissues and affect the quality of life of patients. In recent years, the development of targeted therapy and integrated diagnosis and treatment (theranostics) technology has provided new possibilities for the precise treatment of tumors. Among them, near-infrared fluorescence imaging technology has been widely used in real-time imaging and diagnosis of tumors due to its advantages such as good tissue penetration and low background noise.

[0003] However, fluorescent probes in the prior art generally have the problem of insufficient specificity and difficulty in producing clear, high-contrast imaging in their applications. This is mainly due to the fact that the fluorophores used in fluorescent probe systems generally have the defect of a short half-life in vivo, which leads to an increase in nonspecific background signals. In addition, the passive accumulation of fluorescent probes in normal tissues further exacerbates the problem of these nonspecific background signals, resulting in the continued presence of background fluorescent signals, which seriously reduces the specificity and accuracy of imaging. Summary of the invention

[0004] In order to solve the problems existing in the above-mentioned prior art, the purpose of the present invention is to provide a novel PEGylated near-infrared fluorescent diagnostic and therapeutic probe for ERα targeted diagnosis and treatment, which integrates the PEGylation strategy with the tumor microenvironment response mechanism, and connects 7-oxabicyclo[2.2.1]heptenesulfonamide with efficient ERα protein degradation function with the PEG-modified fluorophore dicyanomethylene-4H-pyran through an ester bond. Through this integration strategy, the present invention achieves precise targeted drug delivery, and utilizes the tumor microenvironment response mechanism to enhance the retention ability of the fluorophore in the tumor, providing high contrast and lasting in vivo tumor imaging effects. The probe can effectively inhibit the growth of MCF-7 breast cancer cells in vivo and realize real-time monitoring of ERα protein degradation, thereby achieving a breakthrough in the accuracy and effect of breast cancer treatment.

[0005] Another object of the present invention is to provide a method for preparing a near-infrared fluorescent diagnostic and therapeutic probe that can monitor ERα protein degradation in real time. The method connects 7-oxabicyclo[2.2.1]heptenesulfonamide with high-efficiency ERα protein degradation function with polyethylene glycol-modified near-infrared fluorophore dicyanomethylene-4H-pyran, and combines the tumor microenvironment response mechanism to design and prepare a probe that can be used for breast cancer diagnosis and treatment.

[0006] Another object of the present invention is to provide an application of a near-infrared fluorescent diagnostic probe prepared by the above preparation method in tumor imaging and treatment of breast cancer. When used in vivo, the probe can effectively inhibit the growth of MCF-7 breast cancer cells and achieve real-time monitoring of ERα protein degradation, thereby making significant progress in improving the accuracy and efficacy of breast cancer treatment.

[0007] To achieve the above object, the present invention provides the following technical solutions:

[0008] An ERα-targeted PEGylated near-infrared fluorescent probe having a structure shown in the following general formula:

[0009]

[0010] A method for preparing the aforementioned ERα-targeted PEGylated near-infrared fluorescent probe comprises the following steps:

[0011] S1. Under alkaline conditions, dicyanomethylene-4H-pyran derivatives and tert-butyl-3-(2-(2-(2-bromoethoxy)-ethoxy)ethoxy)propionate are dissolved in an appropriate amount of N,N-dimethylformamide, and an inorganic base such as K2CO3 or Na2CO3 is added, and stirred at 40-70°C for 4-8 hours. After the reaction is completed, the reaction mixture is poured into an appropriate amount of deionized water and extracted with dichloromethane. After the organic layers are combined, they are washed with water and saturated brine, dried over anhydrous Na2SO4, filtered and concentrated. The resulting crude product is purified by column chromatography to obtain compound (I).

[0012] S2. Dissolve compound (I) in an appropriate amount of anhydrous dichloromethane. Add an appropriate amount of trifluoroacetic acid (TFA) dropwise at 0-5°C. After the addition, warm the reaction mixture to room temperature and stir for 2-4 hours. After the reaction is completed, wash the mixture with saturated brine, and evaporate the organic layer under reduced pressure. The resulting crude product is purified by column chromatography to obtain compound (II).

[0013] S3. Under nitrogen protection, compound (II) is dissolved in an appropriate amount of anhydrous N,N-dimethylformamide (DMF). Subsequently, dicyclohexylcarbodiimide (DCC) and 1-hydroxybenzotriazole (HOBt) are added to the reaction mixture. Then, N-(4-hydroxyphenyl)-N-(2,2,2-trifluoroethyl)vinylsulfonamide (IV) and N,N-diisopropylethylamine (DIPEA) are added at 0°C. After stirring the reaction mixture for 10 to 30 minutes, the temperature is raised to room temperature and stirring is continued for 8 to 12 hours. After the reaction is completed, the reaction solution is quenched with water and extracted with dichloromethane (CH2Cl2). The combined organic layer is washed with water and saturated brine, then dried over anhydrous sodium sulfate (Na2SO4), filtered and concentrated. The crude product is purified by column chromatography to obtain compound (III).

[0014] S4, compound (III) and 4,4'-(furan-3,4-diyl)diphenol (V) are dissolved in an appropriate amount of anhydrous tetrahydrofuran under a nitrogen atmosphere. The reaction mixture is reacted at 70-90°C for 8-12 hours. Then, the reaction mixture is extracted with ethyl acetate (EA) and water (H2O). The organic phase is concentrated and further purified by column chromatography to obtain the final target fluorescent diagnostic probe P1.

[0015] The synthetic route is as follows:

[0016]

[0017] (a) K2CO3, DMF; (b) TFA, CH2Cl2, rt; (c) DCC, HOBt, DIPEA, DMF, rt; (d)

[0018] 4,4'-(Furan-3,4-diyl)diphenol,THF,reflux.

[0019] Furthermore, in step S1, the molar ratio of dicyanomethylene-4H-pyran derivative, tert-butyl-3-(2-(2-(2-bromoethoxy)-ethoxy)ethoxy)propionate and potassium carbonate / sodium carbonate is 1.0:1.0~2.0:2.0~3.0.

[0020] Furthermore, in step S2, the molar ratio of compound (I) to trifluoroacetic acid is 1:0.4-1.0.

[0021] Furthermore, in step S3, the molar ratio of compound (II), dicyclohexylcarbodiimide, 1-hydroxybenzotriazole, N-(4-hydroxyphenyl)-N-(2,2,2-trifluoroethyl)vinylsulfonamide and N,N-diisopropylethylamine is 1.0:1.2-1.5:1.2-1.5:1.0-1.2:2.0-4.0.

[0022] Furthermore, in step S4, the molar ratio of compound (III) to 4,4'-(furan-3,4-diyl)diphenol is 1.0:1.0-2.0.

[0023] Accordingly, the present invention also provides a use of the aforementioned ERα-targeted PEGylated near-infrared fluorescent probe in tumor imaging and treatment of breast cancer, wherein:

[0024] A. The probe can effectively inhibit tumor cell growth in vivo in the MCF-7 breast cancer model, and produce high-contrast and long-lasting fluorescence imaging while achieving degradation of ERα protein in MCF-7 cells.

[0025] B. The probe showed its superiority in real-time visualization, improving treatment effect and reducing treatment toxicity in breast cancer treatment. The experimental results showed that due to the overexpressed esterase in cancer cells, the probe could be efficiently hydrolyzed to release 7-oxabicyclo[2.2.1]heptenesulfonamide and PEG-modified dicyanomethylene-4H-pyran. The released 7-oxabicyclo[2.2.1]heptenesulfonamide showed a strong inhibitory effect on MCF-7 cells, IC 50 The value is 1.09 μM, and its mechanism of action is as follows Figure 1 shown.

[0026] C. Due to the enhanced permeability and retention effect (EPR), the PEGylated dicyanomethylene-4H-pyran showed significant imaging ability in mice, with imaging duration lasting up to 12 days. This probe is expected to be used as a diagnostic probe for ERα-positive breast cancer, providing dual functions of treatment and diagnosis.

[0027] Through the above technical solutions, the present invention demonstrates great potential in the diagnosis and treatment of breast cancer, and provides a new solution for targeted treatment and precision medicine of tumors.

[0028] Compared with the prior art, the advantages and beneficial effects of the present invention are:

[0029] 1. The probe of the present invention has high targeting efficiency and can efficiently target and bind to ERα, thereby achieving specific effects in breast cancer cells and improving the accuracy of treatment.

[0030] 2. The probe of the present invention has enhanced imaging capability. Through PEG modification of the fluorophore, the retention and stability of the fluorophore in the tumor are enhanced, achieving high-contrast persistent imaging.

[0031] 3. The probe of the present invention has real-time monitoring capability and can monitor the degradation process of ERα protein in real time, providing dynamic evaluation of tumor treatment effects.

[0032] 4. The probe of the present invention has excellent anti-tumor effect and can effectively inhibit the proliferation of MCF-7 breast cancer cells in vivo, providing a new strategy and method for the treatment of breast cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:

[0034] Figure 1 Schematic diagram of the design and action mechanism of a PEGylated near-infrared fluorescent therapeutic probe for ERα targeted therapy.

[0035] Figure 2 The optical properties of the probe. Among them, (A): Absorption and emission spectra at a concentration of 10μM in DMSO / PBS (10 / 90, v / v, pH = 7.4) solution. (B): Curve of the relationship between fluorescence intensity and concentration. (C): Fluorescence spectra of dicyanomethylene-4H-pyran (10μM) and probe P1 (in DMSO / PBS solution, 1:1, v / v, pH = 7.4, 10mM, 0.2U / ml esterase). (D): Fluorescence response to various cell analytes; 1. Blank; 2. NaCl; 3. KCl; 4. MgCl2; 5. CaCl2; 6. NaNO2; 7. NaHCO3; 8. Cys; 9. Ser; 10. Leu.

[0036] Figure 3Is the cell inhibitory activity. Among them, (A): Cell inhibitory activity determination of MCF-7 cells. 1. 7-Oxabicyclo[2.2.1]heptenesulfonamide (1μM); 2. Probe P1 (5μM) + esterase (0.1U / mL); 3. Probe P1 (5μM). (B): IC of probe P1 and 4-OHT in MCF-7 cells 50 Experimental values ​​are the mean ± standard deviation (mean ± SD) of at least three independent experiments, **p < 0.01.

[0037] Figure 4 The degradation activity of probe P1. Among them, (A): The degradation activity of probe P1 was evaluated by Western blot experiment. (B): Comparative evaluation of the degradation activity of probe P1 and 7-oxabicyclo[2.2.1]heptenesulfonamide. (C): The degradation mechanism of probe P1 was explored. MCF-7 cells were treated with P1, MG132 or a combination of the two for 24 hours, and the level of ERα was analyzed.

[0038] Figure 5 Confocal laser scanning microscopy (CLSM) imaging analysis of probe P1 at different time points. (A): DAPI staining was used for intracellular localization (blue). (B): Fluorescence image of MCF-7 cells after co-incubation with probe P1 (10.0 μM). (C): Overlay effect of (A) and (B). Scale bar: 50 μm.

[0039] Figure 6 In vivo real-time near infrared (NIR) imaging of MCF-7 transplanted BALB / c mice. (A) NIR imaging timeline after injection of probe P1. (B) NIR imaging at different time points after injection of probe P1 (0.05 mg / kg). DETAILED DESCRIPTION

[0040] The outstanding features of the present invention are further illustrated by the following examples, which are intended only to illustrate the present invention but not to limit the present invention.

[0041] Example 1

[0042] Preparation of tert-butyl (E)-3-(2-(2-(2-(2-(2-(4-(dicyanomethylene)-4H-chromen-2-yl)vinyl)-5-(diethylamino)phenoxy)ethoxy)ethoxy)ethoxy)propanoate (Compound I):

[0043] (E)-2-(2-(4-(diethylamino)-2-hydroxyphenylvinyl)-4H-chromen-4-ylidene)malononitrile (350 mg, 912.8 μmol) and tert-butyl-3-(2-(2-(2-bromoethoxy)-ethoxy)ethoxy)propionate (342.6 mg, 1.0 mmol) were dissolved in DMF (50 mL), K2CO3 (252.3 mg, 1.83 mmol) was added, and the mixture was stirred at 50°C for 4.5 hours. After the reaction was completed, the obtained mixed product was poured into water (150 mL) and extracted with CH2Cl2 (3×50 mL). After the organic phase was combined, it was washed with water and saturated brine, dried over anhydrous Na3SO4, filtered and concentrated. The obtained concentrated product was purified by column chromatography (CH2Cl2 / MeOH=50:1) to obtain compound I (524.74 mg, yield: 89%). 1 H NMR(400MHz,DMSO-d6)δ8.74–8.67(m,1H),7.92–7.84(m,2H),7.72–7.65(m,1H),7.59–7.5 2(m,2H),7.09(d,J=15.8Hz,1H),6.74(s,1H),6.40–6.35(m,1H),6.21(d,J=2.3Hz,1H),4.2 5–4.18(t,J=4.5Hz,2H),3.91–3.84(t,J=4.4Hz,2H),3.74–3.67(m,2H),3.62–3.55(m,2H) ,3.52–3.41(m,11H),2.36–2.28(t,J=6.2Hz,2H),1.34(s,9H),1.16–1.09(t,J=6.9Hz,6H). 13 C NMR(151MHz,DMSO-d6)δ170.3,162.3,160.4,159.8,152.2,152.0,151.3,135.8,134.8,131.1,125.8,124.5,118.7,118.0,117.3,11 6.7,112.0,111.2,105.1,104.3,94.7,79.6,70.2,70.0,69.7,69.6,69.0,67.8,66.2,56.3,54.9,48.6,44.0,35.8,30.8,27.7,12.6.

[0044] Example 2

[0045] Preparation of (E)-3-(2-(2-(2-(2-(2-(4-(dicyanomethylene)-4H-chromen-2-yl)vinyl)-5-(diethylamino)phenoxy)ethoxy)ethoxy)ethoxy)propanoic acid (Compound II):

[0046] Tert-butyl (E)-3-(2-(2-(2-(2-(2-(4-(dicyanomethylene)-4H-chromen-2-yl)vinyl)-5-(diethylamino)phenoxy)ethoxy)ethoxy)ethoxy)propanoate (Compound I) (500 mg) was dissolved in 100 mL of anhydrous dichloromethane (CH2Cl2) and placed in an ice bath. Then 10 mL of trifluoroacetic acid (TFA) was added dropwise. After the addition was completed, the temperature was raised to room temperature and the reaction was stirred for 2 hours. The resulting mixed product was then washed with saturated brine, and the organic phase was evaporated under reduced pressure. The resulting crude product was purified by column chromatography (CH2Cl2 / MeOH=50:1) to obtain Compound II (424.47 mg, yield: 93%). 1 HNMR(400MHz, DMSO-d6)δ8.70(d,J=8.2Hz,1H),7.91–7.82(m,2H),7.68(d,J=8.3Hz, 1H),7.60–7.52(m,2H),7.08(d,J=15.8Hz,1H),6.73(s,1H),6.41–6.33(m,1H),6.19 (d,J=2.3Hz,1H),4.25–4.18(m,2H),3.91–3.84(m,2H),3.75–3.68(m,2H),3.62–3.5 5(m,3H),3.54–3.44(m,9H),2.39–2.32(t,J=6.4Hz,2H),1.16–1.10(t,J=6.9Hz,6H).

[0047] Example 3

[0048] Preparation of 4-(N-(2,2,2-trifluoroethyl)vinylsulfonamido)phenyl(E)-3-(2-(2-(2-(2-(4-(dicyanomethylene)-4H-chromen-2-yl)vinyl)-5-(diethylamino)phenoxy)ethoxy)ethoxy)ethoxy)propanoate (Compound III):

[0049] Under nitrogen protection, (E)-3-(2-(2-(2-(2-(2-(4-(dicyanomethylene)-4H-chromen-2-yl)vinyl)-5-(diethylamino)phenoxy)ethoxy)ethoxy)ethoxy)propanoic acid (Compound II) (320 mg, 544.52 μmol) was dissolved in 50 mL of anhydrous N,N-dimethylformamide (DMF). Then, DCC (134.82 mg, 653.82 μmol) and HOBt (88.29 mg, 653.82 μmol) were added. Subsequently, N-(4-hydroxyphenyl)-N-(2,2,2-trifluoroethyl)vinylsulfonamide (153.2 mg, 544.52 μmol) and DIPEA (281.51 mg, 2.18 mmol) were added in sequence at 0°C. After stirring for 10 minutes, the mixture was heated to room temperature and stirred for 12 hours. After the reaction was completed, the obtained mixed product was quenched with water and extracted three times with dichloromethane (CH2Cl2). The organic phase was combined and washed with water and saturated brine, then dried over anhydrous sodium sulfate (Na2SO4), filtered and concentrated. The obtained crude product was purified by column chromatography (CH2Cl2 / MeOH=150:1) to obtain compound III (194.6 mg, yield: 42%). 1 H NMR (400MHz, DMSO-d6) δ8.73–8.66(m,1H),7.92–7.81(m,2H),7.71–7.64(m,1H),7.59–7.50(t,J=7.7Hz,2H),7.43–7. 37(m,2H),7.18–7.07(m,3H),7.02–6.92(m,1H),6.75(s,1H),6.38(m,1H),6.20(d,J=2.3Hz,1H),6.15(d,J=9.9Hz,1H) ,6.03(d,J=16.4Hz,1H),4.51–4.41(t,J=8.8Hz,2H),4.21(d,J=5.1Hz,2H),3.91–3.84(t,J=4.6Hz,2H),3.75–3.69(m, 2H),3.68–3.63(t,J=6.2Hz,2H),3.62–3.58(m,2H),3.55–3.44(m,8H),2.77–2.71(m,2H),1.16–1.10(t,J=6.9Hz,6H). 13C NMR(151MHz,DMSO-d6)δ169.7,162.3,160.3,159.8,152.2,152.0,151.3,150.1,136 .4,135.8,134.8,133.7,131.1,130.2,129.8,125.7,124.5(q,J=152.7Hz),122.6,11 8.6,118.0,117.3,116.7,112.0,111.2,105.1,104.3,94.7,70.2,70.0,69.7,69.0, 67.7, 65.8, 56.3, 54.9, 51.4 (q, J = 70.6Hz), 44.0, 35.8, 34.7, 30.8, 16.9, 16.4, 12.6. 19 F NMR (376MHz, DMSO-d6) δ-69.6.

[0050] Example 4

[0051] Preparation of ERα-targeted PEGylated near-infrared fluorescent probe:

[0052] Under a nitrogen atmosphere, 4-(N-(2,2,2-trifluoroethyl)vinylsulfonamido)phenyl (E)-3-(2-(2-(2-(2-(4-(dicyanomethylene)-4H-chromen-2-yl)vinyl)-5-(diethylamino)phenoxy)ethoxy)ethoxy)ethoxy)propanoate (Compound III) (135 mg, 158.65 mmol) and 4,4'-(furan-3,4-diyl)diphenol (40 mg, 158.65 mmol) were dissolved in anhydrous tetrahydrofuran (100 mL), heated to 90°C and refluxed for 12 hours. The obtained mixed product was extracted with ethyl acetate (EA) and water (H2O) in sequence, the obtained organic phase was concentrated, and the concentrate was further purified by column chromatography (CH2Cl2 / MeOH=150:1) to obtain an ERα-targeted PEGylated near-infrared fluorescent probe labeled as P1 (117.3 mg, yield: 67%). 1H NMR(400MHz,DMSO-d6)δ9.71(s,1H),9.68(s,1H),8.72–8.65(m,1H),7.90–7.81(m,2H),7.70–7.63(m,1H),7.57–7.50(m,2H),7.46–7.36(m,2H),7.14–7.04(m,7H),6.76–6.70(m,3H),6.70–6.66(m,2H),6.41–6.31(m,1H),6.28(d,J=2.3Hz,1H),5.47(d,J=1.2Hz,1H),5.33–5.29(m,1H),4.57(d,J=9.1Hz,2H),4.26–4.15(t,J=4.4Hz,2H),3.89–3.83(t,J=4.5Hz,2H),3.74–3.68(m,2H),3.67–3.63(t,J=6.2Hz,2H),3.60(s,3H),3.55–3.43(m,8H),2.77–2.70(t,J=6.2Hz,2H),1.87(d,J=6.7Hz,2H),1.14–1.09(t,J=7.0Hz,6H)。 13 C NMR(151MHz,Chloroform-d)δ169.9,162.9,160.6,160.4,157.3,157.1,156.5,155.9,153.2,152.7,151.4,150.6,141.1,137.1,136.7,136.4,134.2,130.4,129.7,129.3,128.4,125.8,125.7,124.0(q,J=150.5Hz),123.0,118.6,118.3,118.2,116.3,115.9,115.7,113.3,112.1,105.3,105.1,95.0,84.8,82.9,80.0,71.2,70.8,70.6,70.5,69.9,67.8,66.6,61.8,58.3,52.9(q,J=75.5Hz),49.5,44.9,38.9,36.8,35.3,34.1,31.8,25.7,25.1,12.9。 19 F NMR(376MHz,DMSO-d6)δ-69.4。HRMS(ESI,positive)m / z calcd for[M+H] + C 59 H 57 F3N4O 12S:1103.3646,found:1103.3719.

[0053] Example 5

[0054] The probe P1 prepared in Example 4 was prepared into a 10 mM dimethyl sulfoxide (DMSO) stock solution, and then diluted to a final concentration of 10 μM using a 10:90 volume ratio DMSO / phosphate buffer (PBS) solution (pH 7.4). The ultraviolet spectrum of P1 was measured using a SHIMADZU UV-2600 UV-visible spectrophotometer, and its fluorescence spectrum was measured using a HITACHI F-4600 fluorescence spectrophotometer. In the anti-interference experiment, 100 μM of cations (Na + , K + Mg 2+ and Ca 2+ ), anions (Cl - , NO2, HCO3) and amino acids (cysteine ​​(Cys), serine (Ser) and leucine (Leu)) were used as interfering substances. These interfering substances were added to 10 μM P1 solution respectively. At 37°C, the fluorescence emission intensity at 682 nm was measured using a HITACHI F-4600 fluorescence spectrophotometer (slit width of 10 / 10 nm) with an excitation wavelength of 550 nm.

[0055] Absorption spectrum studies show that the probe exhibits its main absorption peak at 562nm. Under 562nm excitation, the maximum emission wavelength (λem) of the probe is 682nm, showing a significant Stokes shift of 120nm (e.g. Figure 2 As shown in A). Figure 2 As shown in Figure B, within the concentration range of 0-75 μM, the fluorescence intensity is linearly related to the concentration. However, when the concentration exceeds 75 μM, quenching or saturation of the fluorescence intensity is observed, resulting in the increase in fluorescence intensity no longer being linear. In further experiments, the spectra of the unmodified fluorophore and the probe treated with esterase were compared. The results showed that the spectral positions and shapes of the two were similar, indicating that the fluorescent group and the probe treated with esterase have similar optical properties and their fluorescence intensities are almost the same (e.g. Figure 2 C). In potential applications in simulated biological systems, the analytes were tested with various biologically relevant analytes, including 100 μM cations (such as Na + , K + Mg 2+ and Ca 2+ ) and 100 μM anions (such as Cl - 、NO 2- , HCO 3-), the probe showed its excellent selectivity. In addition, under similar conditions, the probe's selective interference experiment for amino acids such as cysteine ​​(Cys), serine (Ser) and leucine (Leu) showed that the probe of the present invention showed minimal fluorescence changes under these conditions ( Figure 2 D).

[0056] Example 6

[0057] 1. The inhibitory activity of the probe P1 prepared in Example 4 on the proliferation of MCF-7 cells was evaluated using the Cell Counting Kit-8 (CCK-8) method.

[0058] MCF-7 cells were cultured at 1 × 10 4 The cells were seeded in a 96-well plate at a density of 10 cells / mL and cultured at 37°C for 24 h. Subsequently, different concentrations of P1 were added to the cell culture medium and cultured for another 24 h. After the culture was completed, the culture medium was replaced with fresh medium and CCK-8 reagent was added. The absorbance (OD) was measured at a wavelength of 450 nm. IC was calculated based on the OD value. 50 The value is the concentration of P1 that inhibits cell proliferation by 50%. Four replicates were set for each drug concentration, and three independent experiments were performed.

[0059] The present invention uses CCK-8 method to study the proliferation inhibition activity of the parent compound 7-oxabicyclo[2.2.1]heptenesulfonamide and probe P1 on MCF-7 cells. Figure 3 Compared with the parent compound, probe P1 exhibited similar cytotoxicity in MCF-7 cells and had significant in vitro antiproliferative activity (e.g. Figure 3 A). This may be related to the overexpression of esterase in MCF-7 cells. In addition, the IC 50 The value was 1.09 ± 0.08 μM, slightly higher than the IC of 4-OHT 50 Value (0.62 μM) (as Figure 3 B).

[0060] 2. The ability of the probe P1 prepared in Example 4 to induce ERα degradation in MCF-7 cells was evaluated by Western blotting (WB).

[0061] MCF-7 cells were cultured at 1 × 10 6The cells were seeded in 6-well plates at a density of 10 cells and cultured at 37°C for 24 hours. Subsequently, different concentrations of probe P1 were added to the cell culture medium and cultured for another 48 hours. A blank control group and a fulvestrant control group were set up at the same time. The cells were collected and washed twice with PBS. SDS lysis buffer (Beyotime) was used for cell lysis and total protein was extracted. Subsequently, the extracted protein samples were mixed with SDS-PAGE loading buffer and boiled for 5 minutes. An equal amount of protein samples was loaded onto an 8% SDS-PAGE gel for electrophoresis separation, and the gel after electrophoresis was transferred to a PVDF membrane. The PVDF membrane was incubated with the ERα primary antibody (1:1000 dilution) at 4°C overnight. After washing with TBST, it was incubated with the secondary antibody (HRP-labeled secondary antibody, 1:5000 dilution) at room temperature for 1 hour. Finally, the ECL luminescence kit was used for color development.

[0062] The probe of the present invention not only has excellent inhibitory activity, but also has good degradation activity in MCF-7 cells (e.g. Figure 4 A). The parent compound 7-oxabicyclo[2.2.1]heptenesulfonamide is a novel selective estrogen receptor degrader (SERD) that can effectively inhibit the proliferation of MCF-7 cells and exhibit significant ERα degradation efficacy. In order to evaluate the degradation activity of the probe of the present invention, this study also compared the degradation activity of 7-oxabicyclo[2.2.1]heptenesulfonamide and the probe of the present invention after esterase acceleration treatment. After adding 0.1U / mL esterase for acceleration, the results showed that the degradation activity of the probe of the present invention was improved and was basically consistent with the degradation activity of 7-oxabicyclo[2.2.1]heptenesulfonamide (as shown in FIG. Figure 4 B). This further indicates that excess esterase can induce hydrolysis of the probe of the present invention. In addition, this study found that the proteasome inhibitor MG132 can partially block the ERα degradation caused by the probe of the present invention, while MG132 alone has no effect on the expression of ERα protein. These results indicate that the degradation mechanism of the probe of the present invention is derived from the proteasome-dependent mechanism of 7-oxabicyclo[2.2.1]heptenesulfonamide (such as Figure 4 C).

[0063] Example 7

[0064] Based on the experimental results of the above-mentioned Examples 5 and 6, the imaging ability of the probe P1 prepared in Example 4 was further evaluated in vitro and in vivo, including its performance in MCF-7 cells and mouse models. First, the uptake and distribution of the probe of the present invention in cells were evaluated using confocal laser scanning microscopy (CLSM). MCF-7 cells were co-cultured with 1.0 μM of the probe of the present invention, and the corresponding fluorescence images were obtained. Figure 5As shown, after incubation at 37°C for 30 minutes, red fluorescence was observed in the cytoplasm, indicating that the MCF-7 cells effectively took up the probe of the present invention. As time went on, the fluorescence intensity gradually increased, showing that the uptake efficiency of the probe of the present invention in the cells was gradually enhanced. At the same time, it was observed that the number of MCF-7 cells decreased, which is consistent with the degradation effect of the probe of the present invention on ERα.

[0065] In vivo imaging experiments were performed to explore the imaging potential of the probe of the present invention in a living system. The probe of the present invention (0.05 mg / kg) was injected into 6-week-old BALB / c mice carrying MCF-7 breast cancer xenografts via the tail vein. Figure 6 As shown, no fluorescence signal was detected within 30 minutes after the injection of the probe of the present invention. However, fluorescence appeared at the tumor site 2 hours after injection, and the fluorescence intensity increased over time. Significantly, the strongest fluorescence signal in the entire tumor area was observed within 24 hours. Importantly, no fluorescence signal was detected in other organs of the mouse, showing that the probe of the present invention has excellent specificity for tumors. To further verify the long-term retention of the probe of the present invention at the tumor site, the imaging time was extended to 2 weeks. The results showed that relatively strong fluorescence signals could still be detected at the tumor site after 2 weeks. These findings combined show that the probe of the present invention has excellent tumor specificity and long-term retention ability, highlighting its potential as a therapeutic diagnostic agent for real-time fluorescence-guided diagnosis and treatment.

[0066] The above description is only a specific implementation of the present invention, and the protection scope of the present invention is not limited thereto. Any person familiar with the technology can understand and think of any changes or substitutions within the technical scope disclosed by the present invention, which should be included in the scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.

Claims

1. An ERα-targeted PEGylated near-infrared fluorescent probe, characterized in that: Its structural formula is as follows:

2. The method for preparing the ERα-targeted PEGylated near-infrared fluorescent probe according to claim 1, characterized in that: The steps include: S1. Under alkaline conditions, dicyanomethylene-4H-pyran derivatives and tert-butyl-3-(2-(2-(2-bromoethoxy)-ethoxy)ethoxy)propionate undergo Williamson ether preparation reaction to generate a compound of formula (I), and the reaction formula is as follows: S2. Under acidic conditions, the compound of formula (I) is deprotected to generate a compound of formula (II), and the reaction formula is as follows: S3. Under the condition of nitrogen protection and the presence of a condensation reagent, the compound of formula (II) is condensed with N-(4-hydroxyphenyl)-N-(2,2,2-trifluoroethyl) vinyl sulfonamide to generate vinyl sulfonamide derivative (III), and the reaction formula is as follows: S4. Under nitrogen protection, the ethylene sulfonamide derivative (III) reacts with 4,4'-(furan-3,4-diyl)diphenol to undergo a Diels-Alder reaction to generate the ERα-targeted PEGylated near-infrared fluorescent probe, which is labeled as P1. The reaction formula is as follows:

3. The method for preparing the ERα-targeted PEGylated near-infrared fluorescent probe according to claim 2, characterized in that: In step S1, the base is potassium carbonate or sodium carbonate, the reaction solvent is N,N-dimethylformamide, the reaction temperature is 40-70° C., and the reaction time is 4-8 hours; The molar ratio of the dicyanomethylene-4H-pyran derivative, tert-butyl-3-(2-(2-(2-bromoethoxy)-ethoxy)ethoxy)propionate and potassium carbonate or sodium carbonate is 1.0:1.0-2.0:2.0-3.

0.

4. The method for preparing the ERα-targeted PEGylated near-infrared fluorescent probe according to claim 2, characterized in that: In step S2, the acid is trifluoroacetic acid, the reaction solvent is anhydrous dichloromethane, the reaction temperature is room temperature, and the reaction time is 2 to 4 hours; The molar ratio of the compound (I) to trifluoroacetic acid is 1:0.4-1.

0.

5. The method for preparing the ERα-targeted PEGylated near-infrared fluorescent probe according to claim 2, characterized in that: In step S3, the base used is N,N-diisopropylethylamine, the condensing agent is a mixture of dicyclohexylcarbodiimide and 1-hydroxybenzotriazole, the reaction solvent is anhydrous N,N-dimethylformamide, the reaction temperature is room temperature, and the reaction time is 8 to 12 hours; The molar ratio of the compound (II), dicyclohexylcarbodiimide, 1-hydroxybenzotriazole, N-(4-hydroxyphenyl)-N-(2,2,2-trifluoroethyl)vinylsulfonamide and N,N-diisopropylethylamine is 1.0:1.2-1.5:1.2-1.5:1.0-1.2:2.0-4.

0.

6. The method for preparing the ERα-targeted PEGylated near-infrared fluorescent probe according to claim 2, characterized in that: In step S4, the reaction solvent is anhydrous tetrahydrofuran, the reaction temperature is 70 to 90° C., and the reaction time is 8 to 12 hours; The molar ratio of the vinylsulfonamide derivative (III) to 4,4'-(furan-3,4-diyl)diphenol is 1.0:1.0-2.

0.

7. Use of the ERα-targeted PEGylated near-infrared fluorescent probe according to any one of claims 1 to 6 in tumor imaging and treatment of breast cancer, characterized in that: The probe was used for targeted drug delivery, ERα protein degradation and near-infrared fluorescence imaging of ERα-positive breast cancer cells MCF-7.

8. The use according to claim 7, characterized in that: The probe releases 7-oxabicyclo[2.2.1]heptenesulfonamide through esterase activation in MCF-7 cells, thereby inhibiting the proliferation of breast cancer cells.

9. The use according to claim 7, characterized in that The probe has a long-term high-contrast imaging capability in tumor-bearing mice, and the imaging effect can last for more than two weeks.

10. The use according to claim 7 or 8, characterized in that The probe can monitor ERα protein degradation in real time and evaluate the effect of tumor treatment.